The discovery and development of antiretroviral agents

Antiviral Therapy

Volumn 19, Issue , 2014, Pages 5-14

  Lange, Joep M A ^a   Ananworanich, Jintanat ^b,c,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; GENERIC DRUG; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMBINATION CHEMOTHERAPY; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG MANUFACTURE; DRUG QUALITY; DRUG SYNTHESIS; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROVIRUS INFECTION; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMICS; HIV INFECTIONS; INTERNATIONAL COOPERATION; PRACTICE GUIDELINE; QUALITY CONTROL; SUPPLY AND DISTRIBUTION; SYNTHESIS; THERAPEUTIC EQUIVALENCE; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; QUALITY CONTROL; THERAPEUTIC EQUIVALENCY; WORLD HEALTH ORGANIZATION;

EID: 84922149125     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2896     Document Type: Review

References (134)

1. Centers for Disease Control. Pneumocystis pneumonia - Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30:250-252.
2. Centers for Disease Control. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30:409-410.
3. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425-1431.
4. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981; 305:1431-1438.
5. Altman LK. New homosexual disorder worries health officials. New York Times. (Updated 11 May 1982. Accessed 21 July 2014.) Available from http://www.nytimes.com/1982/05/11/science/new-homosexual-disorder-worries-health-officials.html
6. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
7. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224:497-500.
8. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500-503.
9. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984; 225:840-842.
10. Coffin J, Haase A, Levy A, et al. Human immunodeficiency viruses. Science 1986; 232:697.
11. AGM). Science 1986; 232:238-243.
12. Goedert JJ, Biggar RJ, Weiss SH, et al. Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science 1986; 231:992-995.
13. Moss AR, Bachetti P, Osmond D, et al. Seropositivity for HIV and development of AIDS or AIDS-related condition: three year follow-up of the San Francisco General Hospital Cohort. BMJ 1988; 296:745-750.
14. Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 1985; 2:849-852.
15. Worobey M, Han G-Z. The origins and diversification of HIV. In Volberding PA, Greene WC, Lange JMA, Gallant JE, Sewankambo N (Editors). Sande's HIV/AIDS Medicine: Global Care. Philadelphia: Elsevier Saunders 2012; pp. 15-24.
16. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100:663-671.
17. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321:794-799.
18. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211-222.
19. Holmstrup P, Samaranayake LP. Acute and AIDS-related oral candidiasis. In: Samanarayake LP, MacFarlane TW (Editors). Oral candidiasis. London: Wright 1990; pp. 133-155.
20. Elion GB. The purine path to chemotherapy. Science 1989; 244:41-47.
21. Whitley RJ, Gnann J W, Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782-789.
22. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985; 82:7096-7100.
23. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2', 3'-dideoxynucleosides. Proc Natl Acad Sci U S A 1986; 83:1911-1915.
24. Horwitz JP, Chua J, Noel MJ. The monomesylates of 1-(2-deoxy-b-D-lyxofuranosyl) thymines. J Org Chem 1964; 29:2076-2078.
25. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS epidemic. Antiviral Res 2010; 85:1-18.
26. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3'-azido-3'deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; 1:575-580.
27. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185-191.
28. Richman DD, Fischl MA, Grieco MH, et al. The toxicity azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-197.
29. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734.
30. Dolin R. Didanosine. In Dolin R, Masur H, Saag MS (Editors). AIDS Therapy. New York: Churchill Livingstone 2003; pp. 39-56.
31. Bartlett JA. Zalcitabine. In Dolin R, Masur H, Saag MS (Editors). AIDS Therapy. New York: Churchill Livingstone 2003; pp. 57-65.
32. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients in patients with advanced HIV infection who received previous zidovudine therapy. Ann Intern Med 1993; 118:762-769.
33. Schooley RT, Ramirez-Ronda C, Lange JM, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996; 173:1354-1366.
34. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200-500 per cubic millimeter. N Engl J Med 1996; 335:1081-1090.
35. Delta Coordinating Committee. Delta: a randomized doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabline with zidovudine alone in HIV-infected individuals. Lancet 1996; 348:283-291.
36. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276:118-125.
37. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-experienced patients: a randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276:111-117.
38. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-733.
39. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998; 279:930-937.
40. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582-1586.
41. de Jong MD, Loewenthal M, Boucher CA, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994; 169:1346-1350.
42. Levi GC, Vitoria M. Fighting against AIDS: the Brazilian experience. AIDS 2002; 16:2373-2383.
43. Galvão J. Access to antiretroviral therapy drugs in Brazil. Lancet 2002; 360:1862-1865.
44. Nunn AS, Fonseca EM, Bastos FI, et al. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med 2007; 4:e305.
45. Joint United Nations Programme on HIV/AIDS (UNAIDS). New public/private sector effort to accelerate access to HIV/AIDS care and treatment in developing countries 2000. (Accessed 21 July 2014.) Available from http://www.essentialdrugs.org/edrug/archive/200005/msg00027.php
46. Van der Borght S, Rinke de Wit T, Janssens V, Schim van der Loeff M, Rijckborst H, Lange J. HAART for HIV-infected employees of large companies in Africa. Lancet 2006; 368:547-550.
47. Van der Borght S, Janssens V, Schim van der Loeff MF, et al. The accelerating access initiative: experience with a multinational workplace programme in Africa. Bull World Health Organ 2009; 87:794-798.
48. ACHAP - Partnerships for a healthy Africa (Accessed 21 July 2014.) Available from www.achap.org
49. World Health Organization. Commission on Macoreconomics and Health. Macroeconomics and health: investing in health for economic development. (Updated 2001. Accessed 21 July 2014.) Available from http://whqlibdoc.who.int/publications/2001/924154550X.pdf
50. UNAIDS. 2001 Declaration of commitment on HIV/AIDS. (Accessed 21 July 2014.) Available from http://www.unaids.org/en/aboutunaidsunitednationsdeclarationsandgoals/2001declarationofcommitmentonhivaids/
51. World Health Organization. Treating 3 million by 2005: making it happen. (Updated 2003. Accessed 21 July 2014.) Available from http://www.who.int/3by5/publications/documents/en/Treating3millionby2005.pdf
52. The World Bank. The Multi-Country HIV/AIDS Program for Africa (MAP). (Accessed 21 July 2014.) Available from http://web.worldbank.org/WBSITE/EXTERNAL/COUNTRIES/AFRICAEXT/EXTAFRHEANUTPOP/EXTAFRREGTOPHIVAIDS/0,contentMDK:20415735~menuPK:1001234~pagePK:34004173~piPK:34003707~theSitePK:717148,00.html
53. The Global Fund to fight AIDS, Tuberculosis and Malaria. (Accessed 21 July 2014.) Available from www.theglobalfund.org
54. PEPFAR. About PEPFAR. (Accessed 21 July 2014.) Available from http://www.pepfar.gov/about/
55. World Health Organization/UNICEF/UNAIDS. Global update on HIV treatment 2013: results, impact and opportunities. WHO report in partnership with UNICEF and UNAIDS. (Updated June 2013. Accessed 21 July 2014.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/20130630-treatment-report-en.pdf
56. Ford N, Wilson D, Costa Chaves G, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS 2007; 21 Suppl 4:S21-S29.
57. Medicines Patent Pool. (Accessed 21 July 2014.) Available from www.medicinespatentpool.org
58. Clinton Foundation. (Accessed 21 July 2014.) Available from www.clintonfoundation.org/our-work/clinton-health-access-initiative
59. World Health Organization. The strategic use of antiretrovirals to help end the HIV epidemic. (Updated July 2012. Accessed 21 July 2014.) Available from http://apps.who.int/iris/bitstream/10665/75184/1/9789241503921-eng.pdf?ua=1
60. 't Hoen EF, Hogerzeil H V, Quick JD, Sillo HB. A quiet revolution in global public health: The World Health Organization's Prequalification of Medicines Programme. J Public Health Policy 2014; 35:137-161.
61. US Food and Drug Administration. Tentative approval of efavirenz, lamivudine and tenofovir disporoxil fumarate tables. US Department of Health and Human Services. (Updated 1 June 2014. Accessed 21 July 2014.) Available from http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm327644.htm
62. Nakakeeto ON, Elliott BV. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market. Global Health 2013; 9:6.
63. UNITAID. (Accessed 21 July 2014.) Available from http://www.unitaid.eu/en/who/about-unitaid
64. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
65. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
66. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
67. Fätkenheuer G, Nelson M, Lazzarin A. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
68. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
69. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistanct HIV-1 infection. N Engl J Med 2008; 359:355-365.
70. Wainberg MA, Albert J. Can further clinical development of bevirimat be justified. AIDS 2010; 24:773-774.
71. Lalezari J, Latiff GH, Brinson C, et al. Attachment inhibitor prodrug BMS-663068 in ARV-experienced subjects: week 24 analysis. Conference on Retroviruses and Opportunistic Infections. 3-6 March 2014, Boston, MA, USA. Abstract 86.
72. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced patients in DUET 1: 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
73. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced patients in DUET 2: 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
74. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the Phase 3 double-blind randomized ECHO and Thrive trials. J Acquir Immune Defic Syndr 2012; 60:33-42.
75. Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxyl fumarate vs. efavirenz/emtricitabine/tenofovir disoproxyl fumarate in treatment-naive HIV-1-infected adults. AIDS 2014; 28:989-997.
76. Molina J-M, Lamarca A, Andrade Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomized, double-blind, Phase 3, non-inferiority study. Lancet Infect Dis 2012; 12:27-35.
77. Zolopa A, Sax PE, DeJesus E, et al. A randomized doubleblind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 63:96-100.
78. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomized, double-blind, non-inferiority SAILING study. Lancet 2013; 382:700-708.
79. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13:927-935.
80. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type-1-infected patients. J Infect Dis 2013; 208:32-39.
81. Rockstroh JK, DeJesus E, Henry K, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 62:483-486.
82. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. Conference on Retroviruses and Opportunistic Infections. 3-6 March 2013, Atlanta, GA, USA. Abstract 99LB.
83. Morales-Ramirez JO, Gatell JM, Hagins D P, et al. Safety and antiviral effect of MK-1439, a novel NNRTI (+FTC/TDF) in ART-naive HIV-infected patients. Conference on Retroviruses and Opportunistic Infections. 3-6 March 2014, Boston, MA, USA. Abstract 92LB.
84. Camacho R. Generic antiretrovirals: will they change our clinical practice? 12th European Workshop on HIV and Hepatitis: Treatment Strategies and Antiviral Drug Resistance. 26-28 March 2014, Barcelona, Spain.
85. Van 't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54:2042-2050.
86. Spreen WR, Margolis DA, Pottage JC, Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013; 8:565-571.
87. Margolis D, Brinson C, Eron J, et al. 744 and rilpivirine as two-drug oral maintenance therapy: LAI116482 (LATTE) week 48 results. Conference on Retroviruses and Opportunistic Infections. 3-6 March 2014, Boston, MA, USA. Abstract 91LB.
88. Radzio J, Spreen W, Yueh YL, et al. Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures. Conference on Retroviruses and Opportunistic Infections. 3-6 March 2014, Boston, MA, USA. Abstract 40LB.
89. Chen BA, Panther L, Hoesley C, et al. Safety and pharmacodynamics of dapivirine and maraviroc vaginal rings. Conference on Retroviruses and Opportunistic Infections. 3-6 March 2014, Boston, MA, USA. Abstract 41.
90. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed symptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24:1527-1535.
91. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335-343.
92. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27:973-979.
93. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE 2013; 8:e81355.
94. Tuaillon E, Guedin M, Lemee V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004; 37:1543-1549.
95. Ntemgwa M, Brenner BG, Oliveira M, et al. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007; 51:604-610.
96. Ntemgwa ML, d'Aquin Toni T, Brenner BG, et al. Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother 2009; 53:3611-3619.
97. Smith RA, Anderson DJ, Pyrak CL, et al. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009; 199:1323-1326.
98. Boyer PL, Sarafianos SG, Clark PK, et al. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006; 2:e10.
99. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914-920.
100. Garrett N, Xu L, Smit E, et al. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22:1091-1092.
101. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55:813-821.
102. New York State Department of Health AIDS Institute. HIV clinical resource. (Accessed 21 July 2014.) Available from http://www.hivguidelines.org
103. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
104. Poveda E, Rodes B, Toro C, et al. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004; 20:347-348.
105. Puls R and the ENCORE Study Group. A daily dose of 400 mg efavirienz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE-1 study, a randomized, double-blind, placebo-controlled, non-inferiority trial. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 30 June-3 July 2013, Kuala Lumpur, Malaysia. Abstract WELBB01.
106. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. (Updated 2013. Accessed 21 July 2014.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/unaids-global-report-2013-en.pdf
107. Yazdanpanah Y, Lange J, Gerstoft J, Cairns G. Earlier testing for HIV - how do we prevent late presentation? Antivir Ther 2010; 15 Suppl 1:17-24.
108. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
109. Krastinova E, Seng R, Yeni P, et al ANRS PRIMO and COPANA cohorts. Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? PLoS ONE 2013; 8:e71473.
110. van Sighem A, Gras L, Kesselring A, et al HIV Monitoring (SHM). Monitoring report 2013: human immunodeficiency virus (HIV) infection in the Netherlands. (Updated 2013. Accessed 21 July 2014.) Available from http://www.hiv-monitoring.nl/files/5913/8443/2799/SHM-MonitoringReport2013.pdf
111. South Africa: monitoring essential medicines consortium. Report stock outs in South Africa. (Accessed 21 July 2014.) Available from http://www.stockouts.org
112. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health 2011; 16:1297-1313.
113. Mulenga LB, Mwango A, Moyo C, et al. Efficacy of tenofovir disoproxil fumarate/emtricitabine and tenofovir disoproxil fumarate/lamivudine both in combination with efavirenz in antiretroviral-naive, HIV-1-infected Zambians. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 30 June-3 July 2013, Kuala Lumpur, Malaysia. Abstract TULBPE18.
114. Institute for Health Metrics and Evaluation. Financing global health 2012: the end of the golden age? (Updated 2012. Accessed 21 July 2014.) Available from http://www.healthdata.org/sites/default/files/files/policy-report/2012/FGH/IHME-FGH2012-FullReport-HighResolution.pdf
115. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536.
116. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
117. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
118. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. (Updated 2013. Accessed 21 July 2014.) Available from http://www.who.int/hiv/pub/guidelines/arv2013/download/en/
119. Montaner JSG, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the 'HIV Treatment as Prevention' experience in a Canadian setting. PLoS ONE 2014; 9:e87872.
120. World Health Organization. Working together for health: The World Health Report 2006. (Updated 2006. Accessed 21 July 2014.) Available from http://www.who.int/whr/2006/whr06-en.pdf
121. Geng EH, Bwana MB, Muyindike W, et al. Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr 2013; 63:e64-e71.
122. Tweya H, Feldacker C, Estill J, et al. Are they really lost? 'True' status and reasons for treatment discontinuation among HIV-infected patients on antiretroviral therapy considered lost to follow-up in urban Malawi. PLoS ONE 2013; 8:e75761.
123. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198:59-67.
124. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE 2012; 7:e30216.
125. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. (Updated 2012. Accessed 21 July 2014.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-with-annexes-en.pdf
126. Atun R, Knaul FM, Akachi Y, Frenk J. Innovative financing for health: what is truly innovative? Lancet 2012; 380:2044-2049.
127. Schellekens OP, de Beer I, Lindner ME, van Vugt M, Schellekens P, Rinke de Wit TF. Innovation in Namibia: preserving private health insurance and HIV/AIDS treatment. Health Aff (Millwood) 2009; 28:1799-1806.
128. Beaglehole R, Bonita R, Alleyne G, Horton R. NCDs: celebrating success, moving forward. Lancet 2011; 378:1283-1284.
129. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med 2013; 369:1336-1343.
130. Chamie G, Kwarisiima D, Clark TD, et al. SEARCH Collaboration. Leveraging rapid community-based testing campaigns for non-communicable diseases in rural Uganda. PLoS ONE 2012; 7:e43400.
131. Thomas DL. Cure of hepatitis C virus infection without interferon alfa: scientific basis and current clinical evidence. Top Antivir Med 2014; 21:152-156.
132. Gravitz L. A smouldering public-health crisis. Nature 2011; 474:S2-S4.
133. Lawitz E, Poordad F F, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, Phase 2 trial. Lancet 2014; 383:515-523.
134. World Health Organization. The strategic use of antiretrovirals. (Accessed 12 September 2014.) Available from http://apps.who.int/iris/bitstream/10665/75184/1/9789241503921-eng.pdf